Details of the Active Pharmaceutical Ingredient (API)
General Information of API (ID: D00517) | |||||
---|---|---|---|---|---|
Name |
Pentoxifylline
|
||||
Synonyms |
Click to Show/Hide the Synonyms of This API
pentoxifylline; Trental; Oxpentifylline; Pentoxifyllin; Torental; Pentoxyphylline; Dimethyloxohexylxanthine; Pentoxiphyllium; Vazofirin; Pentoxiphylline; Rentylin; 3,7-Dimethyl-1-(5-oxohexyl)xanthine; BL 191; Pentoxyphyllin; 3,7-Dihydro-3,7-dimethyl-1-(5-oxohexyl)-1H-purine-2,6-dione; 1-(5-Oxohexyl)theobromine; 3,7-dimethyl-1-(5-oxohexyl)purine-2,6-dione; 3,7-Dimethyl-1-(5-oxohexyl)-3,7-dihydro-1H-purine-2,6-dione; BL-191; 1H-Purine-2,6-dione, 3,7-dihydro-3,7-dimethyl-1-(5-oxohexyl)-; Pentoxyfilline; 1-(5-Oxohexyl)-3,7-dimethylxanthine; Theobromine, 1-(5-oxohexyl)-; SD6QCT3TSU; UNII-SD6QCT3TSU; 3,7-dimethyl-1-(5-oxohexyl)-1H-purine-2,6(3H,7H)-dione; MFCD00063379; NSC637086; CHEMBL628; NSC 637086; 1,2,3,6-Tetrahydro-3,7-dimethyl-1-(5-oxohexyl)-2,6-purindion; 3,7-Dimethyl-1-(5-oxohexyl)-1H,3H-purin-2,6-dione; MLS000079026; CHEBI:7986; Pentoxyfylline; Azupentat; EHT 0202; NSC-637086; NCGC00015801-02; Durapental; SMR000035998; 3,7-dimethyl-1-(5-oxohexyl)-2,3,6,7-tetrahydro-1H-purine-2,6-dione; DSSTox_CID_3437; DSSTox_RID_77028; DSSTox_GSID_23437; Pentoxifyllinum; Pentoxifilina; Pentoxiphyllin; Hemovas; Ralofect; Vasofirin; Ikomio; Agapurin Retard; Pentoxifilina [INN-Spanish]; Pentoxifyllinum [INN-Latin]; Pentoxil (TN); Trental (TN); CAS-6493-05-6; EHT0201; SR-01000075641; 3,7-Dimethyl-1-(5-oxohexyl)xantine; 3,7-Dimethyl-1-(5-oxohexyl) xantine; Pentoxyifylline; Pentopak; CCRIS 6832; Pentoxifylline (JAN/USP/INN); C04AD03; EHT-201; PTX;Oxpentifylline; EHT-0201; Prestwick_608; EINECS 229-374-5; Pentoxifylline,(S); BRN 0558929; Spectrum_001444; Opera_ID_1800; Prestwick0_000196; Prestwick1_000196; Prestwick2_000196; Prestwick3_000196; Spectrum2_001181; Spectrum3_001820; Spectrum4_000227; Spectrum5_001161; Lopac-P-1784; P 1784; Lopac0_000936; SCHEMBL34039; BSPBio_000151; BSPBio_003439; KBioGR_000893; KBioSS_001924; MLS000758298; MLS001201764; MLS001424051; BIDD:GT0174; DivK1c_000729; SPECTRUM1503611; SPBio_001221; SPBio_002072; BPBio1_000167; GTPL7095; DTXSID7023437; BDBM10850; HMS502E11; KBio1_000729; KBio2_001924; KBio2_004492; KBio2_007060; KBio3_002942; NINDS_000729; HMS1568H13; HMS1922E16; HMS2051N06; HMS2090H13; HMS2093G21; HMS2095H13; HMS2235C16; HMS3262L14; HMS3370D09; HMS3393N06; HMS3712H13; Pharmakon1600-01503611; BCP29306; HY-B0715; ZINC1530776; Tox21_110223; Tox21_500936; BBL016497; CCG-36382; NSC758481; PDSP1_001015; PDSP2_000999; STK177321; AKOS000541484; Tox21_110223_1; AC-8381; DB00806; LP00936; MCULE-9951939936; NC00255; NSC-758481; SDCCGSBI-0050910.P004; VZ33607; 3,7-dimethyl-1-(5-oxohexyl)-xanthine; CAS-1677687; IDI1_000729; NCGC00015801-01; NCGC00015801-03; NCGC00015801-04; NCGC00015801-05; NCGC00015801-06; NCGC00015801-07; NCGC00015801-08; NCGC00015801-09; NCGC00015801-10; NCGC00015801-12; NCGC00015801-17; NCGC00015801-21; NCGC00067069-02; NCGC00067069-03; NCGC00067069-04; NCGC00067069-05; NCGC00178062-01; NCGC00178062-02; NCGC00261621-01; AS-13662; Pentoxifylline [USAN:USP:INN:BAN:JAN]; SBI-0050910.P003; 1-(5-oxohexyl)theobromine (pentoxifylline); AB00052363; EU-0100936; FT-0603570; FT-0657886; FT-0673610; ST50242554; SW196777-4; C07424; D00501; J10071; AB00052363-17; AB00052363_18; AB00052363_21; 5-26-14-00081 (Beilstein Handbook Reference); Q416331; 3,7-dimethyl-1-(5-oxohexyl)-1H-purine-2,6-dione; PTX; Oxpentifylline; BL191; BL 191; BL-191; SR-01000075641-1; SR-01000075641-4; SR-01000075641-7; SR-01000075641-9; BRD-K57569181-001-05-1; BRD-K57569181-001-16-8; 3,7-dimethyl-1-(5-oxohexyl)-3,7-dihydropurine-2,6-dione; 3,7-dimethyl-1-(5-oxohexyl)-1,3,7-trihydropurine-2,6-dione; 3,7-Dimethyl-1-(5-oxohexyl)-3,7-dihydro-1H-purine-2,6-dione #
|
||||
Clinical Status |
Approved
|
||||
Disease Indication | Intermittent claudication | ICD-11: BD40 | [1] | ||
PubChem CID | |||||
Formula |
C13H18N4O3
|
||||
Canonical SMILES |
CC(=O)CCCCN1C(=O)C2=C(N=CN2C)N(C1=O)C
|
||||
InChI |
1S/C13H18N4O3/c1-9(18)6-4-5-7-17-12(19)10-11(14-8-15(10)2)16(3)13(17)20/h8H,4-7H2,1-3H3
|
||||
InChIKey |
BYPFEZZEUUWMEJ-UHFFFAOYSA-N
|
||||
Click to Show/Hide the Molecular Data (Structure/Property) of This API | |||||
Structure |
<iframe style="width: 300px; height: 300px;" frameborder="0" src="https://embed.molview.org/v1/?mode=balls&cid=4740"></iframe>
|
||||
3D MOL | 2D MOL | ||||
Physicochemical Properties | Molecular Weight | 278.31 | Topological Polar Surface Area | 75.5 | |
XlogP | 0.3 | Complexity | 426 | ||
Heavy Atom Count | 20 | Rotatable Bond Count | 5 | ||
Hydrogen Bond Donor Count | 0 | Hydrogen Bond Acceptor Count | 4 | ||
Full List of Drug Formulations (DFMs) Containing This API | ||||||
---|---|---|---|---|---|---|
Pentoxifylline 400 mg tablet | Click to Show/Hide the Full List of Formulation(s): 13 Formulation(s) | |||||
Drug Formulation 1 | DFM Info click to show the detail info of this DFM | |||||
All DIGs | Click to Show/Hide the Full List of DIGs in This DFM
D&c red no. 30; Fd&c blue no. 2; Fd&c yellow no. 6; Magnesium stearate; Titanium dioxide; Triacetin; Hypromellose; Povidone; Cellulose, microcrystalline; Hydroxyethyl cellulose (140 cps at 5%); Polydextrose; Polyethylene glycol
|
|||||
Dosage Form | Extended Release Oral Tablet | |||||
Company | State of Florida DOH Central Pharmacy | |||||
DIG(s) with Biological Activity | ||||||
DIG Name | DIG Info | Representative Biological Activity of This DIG | REF | |||
Sunset yellow FCF | DIG Info | Solute carrier SLCO2B1 (Ki = 68.4 uM) | [2] | |||
FD&C blue no. 2 | DIG Info | Adenosine receptor A3 (IC50 = 1 uM) | [3] | |||
D&C red no. 30 | DIG Info | Heat shock factor 1 (EC50 = 9054 nM) | [4] | |||
Hypromellose | DIG Info | Cytochrome P450 3A5 (IC50 = 19.4 uM) | [5] | |||
Povidone | DIG Info | Cholesterol 25-hydroxylase (IC50 = 78.3 uM) | [5] | |||
Magnesium stearate | DIG Info | Albendazole monooxygenase (Protein expression downregulation) | [6] | |||
Drug Formulation 2 | DFM Info click to show the detail info of this DFM | |||||
All DIGs | Click to Show/Hide the Full List of DIGs in This DFM
D&c red no. 30; Fd&c blue no. 2; Fd&c yellow no. 6; Magnesium stearate; Titanium dioxide; Triacetin; Povidone; Cellulose, microcrystalline; Hydroxyethyl cellulose (140 cps at 5%); Hypromelloses; Polydextrose; Polyethylene glycol
|
|||||
Dosage Form | Extended Release Oral Tablet | |||||
Company | Cardinal Health | |||||
DIG(s) with Biological Activity | ||||||
DIG Name | DIG Info | Representative Biological Activity of This DIG | REF | |||
Sunset yellow FCF | DIG Info | Solute carrier SLCO2B1 (Ki = 68.4 uM) | [2] | |||
FD&C blue no. 2 | DIG Info | Adenosine receptor A3 (IC50 = 1 uM) | [3] | |||
D&C red no. 30 | DIG Info | Heat shock factor 1 (EC50 = 9054 nM) | [4] | |||
Povidone | DIG Info | Cholesterol 25-hydroxylase (IC50 = 78.3 uM) | [5] | |||
Magnesium stearate | DIG Info | Albendazole monooxygenase (Protein expression downregulation) | [6] | |||
Drug Formulation 3 | DFM Info click to show the detail info of this DFM | |||||
All DIGs | Click to Show/Hide the Full List of DIGs in This DFM
D&c red no. 30; Fd&c blue no. 2; Fd&c yellow no. 6; Magnesium stearate; Titanium dioxide; Triacetin; Povidone; Cellulose, microcrystalline; Hydroxyethyl cellulose (140 mpa.s at 5%); Hypromelloses; Polydextrose; Polyethylene glycols
|
|||||
Dosage Form | Extended Release Oral Tablet | |||||
Company | McKesson | |||||
DIG(s) with Biological Activity | ||||||
DIG Name | DIG Info | Representative Biological Activity of This DIG | REF | |||
Sunset yellow FCF | DIG Info | Solute carrier SLCO2B1 (Ki = 68.4 uM) | [2] | |||
FD&C blue no. 2 | DIG Info | Adenosine receptor A3 (IC50 = 1 uM) | [3] | |||
D&C red no. 30 | DIG Info | Heat shock factor 1 (EC50 = 9054 nM) | [4] | |||
Povidone | DIG Info | Cholesterol 25-hydroxylase (IC50 = 78.3 uM) | [5] | |||
Magnesium stearate | DIG Info | Albendazole monooxygenase (Protein expression downregulation) | [6] | |||
Drug Formulation 4 | DFM Info click to show the detail info of this DFM | |||||
All DIGs | Click to Show/Hide the Full List of DIGs in This DFM
D&c red no. 30; Fd&c blue no. 2; Fd&c yellow no. 6; Magnesium stearate; Titanium dioxide; Triacetin; Cellulose, microcrystalline; Hydroxyethyl cellulose (140 cps at 5%); Hypromelloses; Polydextrose; Polyethylene glycols; Povidones
|
|||||
Dosage Form | Extended Release Oral Tablet | |||||
Company | RemedyRepack | |||||
DIG(s) with Biological Activity | ||||||
DIG Name | DIG Info | Representative Biological Activity of This DIG | REF | |||
Sunset yellow FCF | DIG Info | Solute carrier SLCO2B1 (Ki = 68.4 uM) | [2] | |||
FD&C blue no. 2 | DIG Info | Adenosine receptor A3 (IC50 = 1 uM) | [3] | |||
D&C red no. 30 | DIG Info | Heat shock factor 1 (EC50 = 9054 nM) | [4] | |||
Magnesium stearate | DIG Info | Albendazole monooxygenase (Protein expression downregulation) | [6] | |||
Drug Formulation 5 | DFM Info click to show the detail info of this DFM | |||||
All DIGs | Click to Show/Hide the Full List of DIGs in This DFM
D&c red no. 30; Fd&c blue no. 2; Fd&c yellow no. 6; Magnesium stearate; Titanium dioxide; Triacetin; Cellulose, microcrystalline; Hydroxyethyl cellulose (140 mpa.s at 5%); Hypromelloses; Polydextrose; Polyethylene glycols; Povidones
|
|||||
Dosage Form | Extended Release Oral Tablet | |||||
Company | Mylan Pharamceuticals; NCS HealthCare of KY, Inc dba Vangard Labs | |||||
DIG(s) with Biological Activity | ||||||
DIG Name | DIG Info | Representative Biological Activity of This DIG | REF | |||
Sunset yellow FCF | DIG Info | Solute carrier SLCO2B1 (Ki = 68.4 uM) | [2] | |||
FD&C blue no. 2 | DIG Info | Adenosine receptor A3 (IC50 = 1 uM) | [3] | |||
D&C red no. 30 | DIG Info | Heat shock factor 1 (EC50 = 9054 nM) | [4] | |||
Magnesium stearate | DIG Info | Albendazole monooxygenase (Protein expression downregulation) | [6] | |||
Drug Formulation 6 | DFM Info click to show the detail info of this DFM | |||||
All DIGs | Click to Show/Hide the Full List of DIGs in This DFM
Isopropyl alcohol; Magnesium stearate; Talc; Povidone; Hydroxyethyl cellulose (2000 cps at 1%)
|
|||||
Dosage Form | Extended Release Oral Tablet | |||||
Company | PD-Rx Pharmaceuticals; Stat Rx USA | |||||
DIG(s) with Biological Activity | ||||||
DIG Name | DIG Info | Representative Biological Activity of This DIG | REF | |||
Isopropyl alcohol | DIG Info | Lymphoma P388/ADR cells (IC50 = 0.22 uM) | [7] | |||
Povidone | DIG Info | Cholesterol 25-hydroxylase (IC50 = 78.3 uM) | [5] | |||
Magnesium stearate | DIG Info | Albendazole monooxygenase (Protein expression downregulation) | [6] | |||
Drug Formulation 7 | DFM Info click to show the detail info of this DFM | |||||
All DIGs | Click to Show/Hide the Full List of DIGs in This DFM
Isopropyl alcohol; Magnesium stearate; Talc; Povidone
|
|||||
Dosage Form | Extended Release Oral Tablet | |||||
Company | State of Florida DOH Central Pharmacy | |||||
DIG(s) with Biological Activity | ||||||
DIG Name | DIG Info | Representative Biological Activity of This DIG | REF | |||
Isopropyl alcohol | DIG Info | Lymphoma P388/ADR cells (IC50 = 0.22 uM) | [7] | |||
Povidone | DIG Info | Cholesterol 25-hydroxylase (IC50 = 78.3 uM) | [5] | |||
Magnesium stearate | DIG Info | Albendazole monooxygenase (Protein expression downregulation) | [6] | |||
Drug Formulation 8 | DFM Info click to show the detail info of this DFM | |||||
All DIGs | Click to Show/Hide the Full List of DIGs in This DFM
Isopropyl alcohol; Magnesium stearate; Talc; Hydroxyethyl cellulose (2000 mpa.s at 1%)
|
|||||
Dosage Form | Extended Release Oral Tablet | |||||
Company | A-S Medication Solutions; AvKARE; Lake Eire Medical & Surgical Supply DBA Quality Care Products; Physicians Total Care; Teva Pharmaceuticals | |||||
DIG(s) with Biological Activity | ||||||
DIG Name | DIG Info | Representative Biological Activity of This DIG | REF | |||
Isopropyl alcohol | DIG Info | Lymphoma P388/ADR cells (IC50 = 0.22 uM) | [7] | |||
Magnesium stearate | DIG Info | Albendazole monooxygenase (Protein expression downregulation) | [6] | |||
Drug Formulation 9 | DFM Info click to show the detail info of this DFM | |||||
All DIGs | Click to Show/Hide the Full List of DIGs in This DFM
Isopropyl alcohol; Magnesium stearate; Talc; Povidones
|
|||||
Dosage Form | Extended Release Oral Tablet | |||||
Company | Aphena Pharma Solutions-Tennessee; Oceanside Pharmaceuticals | |||||
DIG(s) with Biological Activity | ||||||
DIG Name | DIG Info | Representative Biological Activity of This DIG | REF | |||
Isopropyl alcohol | DIG Info | Lymphoma P388/ADR cells (IC50 = 0.22 uM) | [7] | |||
Magnesium stearate | DIG Info | Albendazole monooxygenase (Protein expression downregulation) | [6] | |||
Drug Formulation 10 | DFM Info click to show the detail info of this DFM | |||||
All DIGs | Click to Show/Hide the Full List of DIGs in This DFM
Magnesium stearate; Talc; Titanium dioxide; Fd&c red no. 3; Povidone; Hypromelloses; Polyethylene glycols
|
|||||
Dosage Form | Extended Release Tablet | |||||
Company | Sanofi-Aventis | |||||
DIG(s) with Biological Activity | ||||||
DIG Name | DIG Info | Representative Biological Activity of This DIG | REF | |||
FD&C red no. 3 | DIG Info | Phosphodiesterase 3A (IC50 = 0.092 uM) | [3] | |||
Povidone | DIG Info | Cholesterol 25-hydroxylase (IC50 = 78.3 uM) | [5] | |||
Magnesium stearate | DIG Info | Albendazole monooxygenase (Protein expression downregulation) | [6] | |||
Drug Formulation 11 | DFM Info click to show the detail info of this DFM | |||||
All DIGs | Click to Show/Hide the Full List of DIGs in This DFM
Magnesium stearate; Titanium dioxide; Silicon dioxide; Hydroxypropyl cellulose (1200000 mw); Hypromellose, unspecified; Polyethylene glycol 8000
|
|||||
Dosage Form | Extended Release Oral Tablet | |||||
Company | Preferred Pharamaceuticals | |||||
DIG(s) with Biological Activity | ||||||
DIG Name | DIG Info | Representative Biological Activity of This DIG | REF | |||
Magnesium stearate | DIG Info | Albendazole monooxygenase (Protein expression downregulation) | [6] | |||
Silicon dioxide | DIG Info | Albendazole monooxygenase (Protein expression downregulation) | [6] | |||
Drug Formulation 12 | DFM Info click to show the detail info of this DFM | |||||
All DIGs | Click to Show/Hide the Full List of DIGs in This DFM
Magnesium stearate; Titanium dioxide; Silicon dioxide; Hydroxypropyl cellulose; Hypromelloses; Polyethylene glycol 8000
|
|||||
Dosage Form | Extended Release Oral Tablet | |||||
Company | Aphena Pharma Solutions-Tennessee; Bryant Ranch Prepack; Golden State Medical Supply | |||||
DIG(s) with Biological Activity | ||||||
DIG Name | DIG Info | Representative Biological Activity of This DIG | REF | |||
Magnesium stearate | DIG Info | Albendazole monooxygenase (Protein expression downregulation) | [6] | |||
Silicon dioxide | DIG Info | Albendazole monooxygenase (Protein expression downregulation) | [6] | |||
Drug Formulation 13 | DFM Info click to show the detail info of this DFM | |||||
All DIGs | Click to Show/Hide the Full List of DIGs in This DFM
Magnesium stearate; Titanium dioxide; Silicon dioxide; Hydroxypropyl cellulose (type h); Hypromelloses; Polyethylene glycol 8000
|
|||||
Dosage Form | Extended Release Oral Tablet | |||||
Company | Aidarex Pharmaceuticals; NuCare Pharmaceuticals | |||||
DIG(s) with Biological Activity | ||||||
DIG Name | DIG Info | Representative Biological Activity of This DIG | REF | |||
Magnesium stearate | DIG Info | Albendazole monooxygenase (Protein expression downregulation) | [6] | |||
Silicon dioxide | DIG Info | Albendazole monooxygenase (Protein expression downregulation) | [6] | |||
If you find any error in data or bug in web service, please kindly report it to Dr. Zhang and Dr. Mou.